Table 6.
Some of the latest nano-based drug combinations to overcome MDR in cancer.
| Drug Delivery System | Treatment Strategy | Loaded with | Cancer Type | Reference |
|---|---|---|---|---|
| Nanoparticulate targeting mitochondria | Downregulation of pump-related proteins that are involved in drug resistance | Mitochondrial complex, P-gp siRNA | Breast cancer | [144] |
| Nanoparticle–peptide drug biconjugate | Enhancement of efficient drug delivery and release | Doxorubicin peptides | H69AR | [148] |
| Folate-decorated polymersome | Combining chemotherapy with P-gp inhibitors | Paclitaxel, doxorubicin, and tariquidar | MDR breast cancer | [149] |
| Polymer–drug conjugate | Bypassing of pumps related to drug efflux | Doxorubicin | Breast cancer | [150] |
| Zinc oxide nanoparticle | Synergistic autophagy with increased reactive oxygen species generation | Doxorubicin and zinc oxide | MCF-7 | [151] |
| Liposome | Its controlled drug release promotes drug accumulation in cancers | Docetaxel (DTX) and dexamethasone (DEX) | KBv Human epidermoid carcinoma |
[152] |